Glucose Regulates the Expression of the Apolipoprotein A5 Gene by Fruchart, Jamila et al.
 1
Glucose Regulates The Expression Of The Apolipoprotein A5 Gene 
 
Maxime Nowak, Audrey Helleboid-Chapman1, Heidelinde Jakel, Emmanuelle Moitrot, 
Corinne Rommens, Len A. Pennacchio, Jamila Fruchart-Najib, Jean-Charles Fruchart 
 
1 Institut Pasteur de Lille, Département d'Athérosclérose, Lille, F-59019 France ;  
2 Inserm, U545, Lille, F-59019 France ;  
3 Université de Lille 2, Lille, F-59006 France ;  
4 Genomics Division and Joint Genome Institute, Lawrence Berkeley National Laboratory, 
Berkeley, California, USA. 
 
*Corresponding author: Dr. Jamila Fruchart 
Parc Eurasanté – Université de Lille 2 
885, Avenue Eugène Avinée. 59120 Loos - France 
E-mail: jamila.fruchart@univ-lille2.fr, Phone: (33)-3-20-16-40-84, Fax: (33)-3-20-16-40-01 
 
Running title: APOA5 gene regulation by glucose 
 
Abbreviations: APOA5, the human apolipoprotein A5 gene; apoa5, the rodent apolipoprotein 
A5 gene; apoA-V, the human protein; PI3K, the phosphatidylinositol 3-kinase; PP1/PP2A, the 
protein phosphatases 1/2A; USF, the upstream stimulatory factor; SREBP-1c, the sterol 
response element binding protein-1c 
 
 2
ABSTRACT 
 
The apolipoprotein A5 gene (APOA5) is a key player in determining triglyceride 
concentrations in humans and mice. Since diabetes is often associated with 
hypertriglyceridemia, this study explores whether APOA5 gene expression is regulated by 
alteration in glucose homeostasis and the related pathways. D-glucose activates APOA5 gene 
expression in a time- and dose-dependent manner in hepatocytes, and the glycolytic pathway 
involved was determined using D-glucose analogs and metabolites. Together, transient 
transfections, electrophoretic mobility shift assays and chromatin immunoprecipitation assays 
show that this regulation occurs at the transcriptional level through an increase of USF1/2 
binding to an E-box in the APOA5 promoter. We show that this phenomenon is not due to an 
increase of mRNA or protein expression levels of USF. Using protein phosphatases 1 and 2A 
inhibitor, we demonstrate that D-glucose regulates APOA5 gene via a dephosphorylation 
mechanism, thereby resulting in an enhanced USF1/2-promoter binding. Last, subsequent 
suppressions of USF1/2 and phosphatases mRNA through siRNA gene silencing abolished the 
regulation. We demonstrate that APOA5 gene is up regulated by D-glucose and USF through 
phosphatase activation. These findings may provide a new cross talk between glucose and lipid 
metabolism. 
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INTRODUCTION 
 
Apolipoproteins play a central role in lipid homeostasis and are intimately associated 
with the cardiovascular disease risk 1; 2. Recently, the gene coding for a new apolipoprotein 
family member, APOA5, was identified to be an important determinant of plasma triglyceride 
levels in both humans and mice 3; 4; 5. Data from mice overexpressing or lacking APOA5 
provide direct evidence that apolipoprotein A5 is inversely correlated with plasma triglyceride 
levels. In humans, polymorphisms across the APOA5 locus have been associated with elevated 
plasma TG concentrations 3; 6, familial combined hypertriglyceridemia 7 and increased risk of 
cardiovascular disease 8; 9. Mechanism underlying the hypotriglyceridemic effect of apoA-V 
protein was evaluated. ApoA-V appears to activate LPL-mediated VLDL-TG hydrolysis, thus 
accelerates VLDL clearance, and reduces plasma TG by inhibiting hepatic VLDL-TG 
production 10; 11; 12. Taken altogether, these data suggest that APOA5 could be a strong 
modulator of triglyceride levels. Therefore, studying the regulation of its gene expression is of 
significant clinical importance for treatment of dyslipidemia. Little is known regarding the 
APOA5 gene regulation, although previous studies showed that different transcription factors 
implicated in triglyceride metabolism regulate the APOA5 gene. Indeed, PPARα, FXR and 
RORα 13; 14; 15; 16 induce the APOA5 gene at the transcriptional level. Moreover, we published 
that the LXR ligand T0901317 down-regulates human APOA5 gene expression through an 
indirect mechanism involving SREBP-1c 17. Last, we reported that insulin inhibits the APOA5 
gene expression through the activation of the phosphatidylinositol 3-kinase (PI3K) signalling 
pathway 18. This work showed for the first time the phosphorylation-dependent binding of 
USF1/2 to a functional E-box element within the APOA5 promoter. Interestingly, in agreement 
with our study, Prieur et al. 19 have reported that the thyroid hormone regulates the 
hypotriglyceridemic gene APOA5 through a synergistic activation with USF. Their report 
combinated with ours raises the possibility of a cross talk between insulin and thyroid signals 
on the same element in APOA5. 
The leading cause of death for diabetes is cardiovascular diseases 20; 21. Diabetes is a 
highly complex pathology inducing perturbation in glucose homeostasis, and 
hypertriglyceridemia is often associated with this metabolic disease. Glucose has been 
implicated as an independent signal in homeostasis of carbohydrate and fatty acids for 
activating the synthesis of glycolytic and lipogenic enzymes. In liver, adipocytes and β-cells, 
glucose is metabolized to generate an intracellular signal that allows for transcriptional 
regulation of metabolic genes. The metabolic pathway involved in the glucose-mediated gene 
regulation is variable, and glucose analogs or metabolites could mimic the glucose response 22; 
23; 24; 25. Recent studies have identified transcription factors such as USF 26; 27, SREBP1-c 28; 29, 
COUP-TFII 30, and ChREBP 31; 32; 33, as mediators of glucose-induced gene regulation. 
However, the mechanism by which glucose regulates the transcriptional activity of these 
factors is still unclear. 
Because we have recently demonstrated the specific implication of USF1/2 in APOA5 
gene regulation by insulin 18, and a forced overexpression of these transcription factors resulted 
in an important increase of the APOA5 transactivation, we have explored the role of USF1/2 in 
this gene regulation after a D-glucose treatment, and the related signalling pathway. Our results 
indicate that USF1/2 bind directly to the promoter of the APOA5 gene in a glucose-dependent 
manner and are absolutely required for its induction by D-glucose. USF1/2 are therefore 
potentially involved in the regulation of genes during alteration in glucose homeostasis and 
metabolic disorders, and could contribute to the development of modulation in triglycerides 
levels. 
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RESULTS 
 
D-glucose increases APOA5 gene expression in a time- and dose-dependent manner in 
human hepatoma cells and primary rat hepatocytes. 
To determine whether D-glucose can modulate APOA5 gene expression, human hepatoma 
HepG2 and HuH7 cells were treated with D-glucose under several different conditions as 
described in Figure 1. The APOA5 mRNA levels were increased in a time-dependent manner to 
reach a maximum of 2.5-fold after 48h treatment with 25mM D-glucose (Fig. 1A). Moreover, 
this up-regulation was found to be D-glucose dose-dependent (Fig. 1B) with a maximal 
stimulatory effect observed with 25mM of D-glucose. Results were confirmed in primary rat 
hepatocytes treated with 25mM of D-glucose for 24h and 48h (Fig. 1C). Thus, human and rat 
APOA5 gene expression were significantly increased after treatment with 25mM of D-glucose 
for 48h. 
 
Identification of the glycolytic pathway involved in the regulation of APOA5 gene 
expression. 
To explore the metabolic pathway involved in the D-glucose response, HuH7 cells were treated 
with several glucose analogs and metabolites (Fig. 2). Compounds were added for 48h in a 
culture medium without D-glucose. L-Glucose, a non-metabolizable sugar, did not influence 
the expression of APOA5 gene, indicating that intracellular processing of D-glucose is needed 
to promote APOA5 induction. To analyse whether the metabolites of the glycolytic pathway 
stimulate APOA5 expression, Lactate, Pyruvate, and Glycerol were tested. None of these 
molecules increases APOA5 mRNA levels, thus indicating that the induction of APOA5 is 
mediated by a glucose-metabolite generated during glycolysis and upstream to triose phosphate 
pathway. To examine whether the pentose pathway is implicated in the D-glucose-dependent 
induction of APOA5, we treated cells with xylitol, a precursor of xylulose-5-phosphate, an 
intermediate of the non-oxidative branch of the pentose phosphate pathway. Xylitol was 
unsuccessful in restoring APOA5 gene induction. To verify whether the hexosamine pathway is 
implicated in this up-regulation, cells were treated with azaserine, an inhibitor of 
glutamine/fructose-6-phosphate amidotransferase, the rate-limiting enzyme in the conversion 
of glucose to glucosamine. The induction of APOA5 expression by 25mM D-glucose was not 
inhibited by azaserine, suggesting that the hexosamine pathway is not implicated. Last, to 
evaluate whether analogs could mediate the D-glucose APOA5 up-regulation, we tested D-
fructose and D-mannose and we observed that both sugars restored the D-glucose dependent-
induction of APOA5. Fructose is phosphorylated to fructose-1-P (F-1-P) and this metabolite 
split into glyceraldehyde (GAD) and dihydroxyacetone phosphate (DHAP). Both sugars give 
glyceraldehydes-3-P (G3P). Moreover, fructose can be phosphorylated into fructose-6-P (F-6-
P) and then metabolized to reach G3P. In the glycolysis pathway, D-glucose is phosphorylated 
to glucose-6-phosphate (G-6-P) by glucokinase and a specific isomerase change G-6-P to F-6-
P. Because D-mannose enters glycolysis at the F-6-P step and pyruvate does not mimic the D-
glucose response, we conclude that the regulation of APOA5 occurs through a metabolite 
during the glycolysis between G3P and pyruvate. A last treatment was done with D-mannitol as 
control to demonstrate that this not an osmotic effect. D-mannitol, which is not transported into 
cells, did not mediate the D-glucose effect. 
 
D-glucose regulates APOA5 gene at the transcriptional level and requires a functional  
E-box in the promoter. 
We performed transient transfections of HepG2 cells to determine if the induction of APOA5 
by D-glucose occurs at the transcriptional level. We observed that 25 mM of D-glucose 
increases the promoter activity in a significant manner after 48h (Fig. 3A). We controlled 
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experiences using transient transfections with the L-PK glucose-responsive promoter. To 
underline the presence of a response element in the promoter, 5’-deletion analyses of the 
human APOA5 promoter were performed (Fig. 3B). We showed that the promoter activity was 
increased by 25mM D-glucose when cells were transfected with both –304/+63 and –146/+63 
fragments. However, D-glucose has no effects when cells were transfected with the –61/+63 
fragment. Moreover, when cells were transfected with a reporter plasmid driven by the APOA5 
promoter fragment –146/+63 in which E-box was mutated (5’-CCCGCG3-3’), APOA5 gene 
was not regulated by D-glucose at the transcriptional level. These results confirm the presence, 
the functionality and the requirement of the E-box element 5’-CACGTG-3’ located at –76/-81 
in the promoter. 
 
D-glucose increases the USF1/2-DNA complex in the human APOA5 promoter. 
Previously, we have demonstrated in our laboratory the binding of USF1 and USF2 18 and 
SREBP-1c 17 to the APOA5 promoter. Thus, we investigated whether these transcription factors 
are involved in APOA5 regulation by D-glucose. We showed with EMSA that treatment of 
cells with D-glucose for 48h increased the binding of nucleoproteins to the APOA5 E-box (Fig. 
4A). Towards this goal, we tested the ability of the specific antibodies anti-USF1, anti-USF2, 
or anti-SREBP-1c to disrupt the binding from the nucleoproteins. Only anti-USF1 and anti-
USF2 antibodies, but not anti-SREBP-1c, were able to disrupt the binding. Specificity of USF 
was confirmed by using in vitro transcribed and translated human protein. Moreover, we found 
that the mutated E-box-containing probe failed to bind USF. To characterize the specific 
binding of USF to the promoter in vitro and in vivo in cells after 48h D-glucose treatment, we 
performed respectively biotinylated oligoprecipitation assays using nuclear extracts followed 
by western blot analyses of USF1 (Fig. 4B) and ChIP assays followed by PCR amplification of 
APOA5 gene (Fig. 4C). In vitro and in vivo association between USF1 and hAPOA5 promoter 
was evaluated after three independent experiments, and results demonstrate a two-fold increase 
after D-glucose treatment. 
 
USF1 and USF2 mRNA and protein levels are not regulated by D-glucose treatment. 
To study the effect of D-glucose on USF1 and USF2 gene expression, we evaluated USF1 and 
USF2 mRNA levels by quantitative RT-PCR after cell treatment with 5mM or 25mM D-
glucose for 48h (Fig. 5A). We conclude that D-glucose does not regulate the expression of the 
USF1 and USF2 gene. Then, to verify the role of D-glucose on the USF1 and USF2 protein 
expression, we performed western blot analyses using specific anti-USF1 or anti-USF2 
antibodies, and nuclear extracts from cell treated with 5mM or 25mM D-glucose for 48h (Fig. 
5B). Quantifications of USF1 or USF2 are expressed in figure 5C as the USF1 or USF2 to β-
actin protein ratio. In both immunoblots, no significant differences for protein expression 
appeared after D-glucose treatment. Thus, D-glucose does not regulate USF1 and USF2 mRNA 
and protein levels  
 
Effect of okadaic acid on the D-glucose-mediated activation of APOA5 gene. 
Since D-glucose treatment did not influence the expression of USF, we investigated whether a 
phosphorylation/dephosphorylation mechanism is involved in the D-glucose signalling 
pathway (Fig. 6). Thus, we tested okadaic acid, a potent inhibitor of type 1 and 2A protein 
phosphatases (PP1/PP2A) the most abundant phosphatases present in the liver known to be 
implicated in the glucose effect. The APOA5 gene expression was evaluated after D-glucose 
treatment in the presence of different concentrations of phosphatases inhibitor. Okadaic acid 
has no inhibitory effects in the lower concentration (0.1 nM), but suppress in part the APOA5 
gene regulation by D-glucose when it is used at 1 nM. At this concentration, only the PP2A 
phosphatase is inhibited. We conclude that D-glucose needs the PP2A activation to regulate the 
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expression of APOA5 gene. Used at 10 nM the okadaic acid completely inhibits both PP1 and 
PP2A protein phosphatases resulting in the suppression of the D-glucose-mediated activation 
of APOA5 mRNA levels. We show here that okadaic acid inhibits in a dose-dependent manner 
the D-glucose-mediated increase of APOA5 gene expression. Thus, to increase the APOA5 
gene expression, D-glucose involved a dephosphorylation mechanism via the PP1/PP2A 
signalling pathway  
 
Effect of USF1, USF2, PP1 and PP2A siRNA on APOA5 gene expression. 
To further examine whether transcription factors and protein phosphatases could mediate the 
D-glucose effect on APOA5 gene regulation, we attempted to suppress the USF1, USF2, PP1 
and PP2A gene products through RNA interference. With quantitative RT-PCR we 
demonstrated that mRNA levels for the target genes were significantly decreased (50%) after 
transfection with siRNA (Fig. 7A). Thus, HuH7 cells were transfected with siRNA to finally 
inhibit the expression of the respective mRNA (Fig. 7B). First, we controlled that APOA5 
mRNA levels were significantly increased after D-glucose treatment when cells were 
transfected with nonspecific control siRNA. Next, we showed that APOA5 mRNA levels were 
not increased after transfection of cells with USF1 siRNA or USF2 siRNA. In conclusion, both 
transcription factors are required for APOA5 gene regulation by D-glucose. Last, we used PP1 
siRNA or PP2A siRNA to demonstrate the implication of these protein phosphatases in APOA5 
gene regulation by D-glucose. In both cases, APOA5 mRNA levels were not increased after D-
glucose treatment. Taken together, these results showed that D-glucose induced APOA5 gene 
regulation via USF1/2 transcription factors and this regulation occurs through the PP1/PP2A 
protein phosphatases signalling pathway. 
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DISCUSSION 
 
APOA5 is a major determinant of triglyceride homeostasis. This, coupled with the fact 
that diabetes-associated hypertriglyceridemia may in part be due to the hypertriglyceridemic 
APOC3 gene overexpression 34, led us to explore the potential regulation of the recently 
identified APOA5 gene by D-glucose. In the present study, we demonstrate that 25mM D-
glucose increases APOA5 gene expression in a time- and dose-dependent in vitro and our 
results suggest that a glucose-metabolite generated during glycolysis between G3P and triose 
phosphate could regulate the expression of APOA5 gene. Since we found that insulin and the 
LXR ligand T0901317 down-regulate APOA5 gene expression through USF phosphorylation 
and SREBP1-c activation respectively 17; 18, we studied here the specificity of the transcription 
factor. We clearly demonstrated that SREBP-1c is not involved and the novelty rests in the fact 
that the D-glucose treatment highly increases the USF1/2 binding to the APOA5 promoter. 
After treatment, expressions of USF1/2 mRNA and protein levels were not modulated by D-
glucose. Thus, in order to explain how D-glucose acts and increases the binding of these 
nucleoproteins, we investigated whether a post-translational modification of USF1/2 is 
involved in cell. Previously, we demonstrated that insulin down-regulates APOA5 gene through 
the PI3K signalling pathway 18. Since an activation of PI3K inhibits APOA5 gene transcription, 
it follows that activation of phosphatases could stimulate APOA5 gene transcription. 
Furthermore, we showed that only the non-phosphorylated form of USF could bind the APOA5 
E-box. Taken together, these results suggested that the association of USF1/2 to the promoter is 
mediated via a phosphorylation/dephosphorylation mechanism. 
There is controversy about the involvement and the action of USF as transcription factor 
mediated in the glucose responsiveness. Findings suggest that USF regulation is complex, with 
possible cell-specific and species-specific regulation of USF proteins by glucose 35. For 
example, although Kahn 26 claims that the binding of USF proteins to the GlRE is not 
modulated by nutritional conditions, others suggested that glucose and insulin regulate the USF 
protein-DNA interactions 36; 37; 38. Moreover, the role of USF in the regulation of glucose-
stimulated L-PK expression in hepatocytes and in insulin-secreting cells is unclear 39; 40; 41; 42. 
Two groups showed contradictory results of the L-PK reporter enzyme activity using transient 
transfection of hepatocytes with USF and dominant-negative USF (DN-USF) 27; 31. However, 
the expression levels of USF and DN-USF were not examined in either study 33. To assess the 
role of USF1/2 in the regulation of APOA5 gene expression, we used an inactivation strategy. 
Suppression of USF1 or USF2 by siRNA assays indicated that both transcription factors are 
linked and act in the heterodimer form to increase APOA5 gene. Indeed, results suggested that 
when USF1 or USF2 is not synthesised, no regulation was observed. This could be explained, 
in part, by the fact that in physiological conditions, mutually USF1 or USF2 alone were not 
able to bind the APOA5 promoter. Moreover, the major USF species present in most tissues 
and cell lines is the heterodimer of USF1 and USF2 35. In the same way, results obtained after 
suppression of PP1 or PP2A suggested that the APOA5 gene is regulated via a dependent role 
of both protein phosphatases. Findings may prove that USF1 and USF2 could be 
dephosphrorylated and involved in the D-glucose regulation only when both PP1 and PP2A are 
present in cell. Taken together, we could hypothesize a potential activation of the protein 
phosphatases signalling pathway, which may induce the nuclear dephosphorylation of USF1/2 
and consequently increase their binding to the promoter, resulting in the transactivation of 
APOA5 gene expression.  
Moreover, it has been well documented that glucose activates the nuclear translocation of an 
other transcription factor distinct from USF, named ChREBP, and suggested by Uyeda et al. 43; 
44 as the regulator of the glucose responsiveness of the L-PK expression. Like us, authors 
proposed that ChREBP activity was regulated acutely in response to high glucose by a series of 
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phosphorylation/dephosphorylation reactions in hepatocytes, with two phosphorylation sites, 
the first located near the nuclear localization signal and the second near the DNA binding 
ability 24; 43. So, it could be interesting to determine the phosphorylation sites present in USF1/2 
transcription factors, that are involved in insulin and glucose response, to give more insights 
into the regulation of APOA5 gene. Dentin et al. 45 demonstrated using siRNA that ChREBP is 
implicated in glucose signalling and regulation of L-PK, FAS or ACC gene expression in 
hepatocytes, but others published that this transcription factor does not act alone to regulate 
these genes. Indeed, Stoeckman et al. 46 demonstrated that ChREBP dimerize with Mlx (Max-
like protein X) and this heterodimer is functional in regulating the expression of glucose-
responsive genes. Then, Ma et al. 47 confirmed that ChREBP and Mlx dimerize and function 
together as the principal mediator of glucose-induced gene expression in the liver. Moreover, 
authors proposed the consensus ChoRE for ChREBP, consisting of two E-box motifs with the 
sequence 5’-CACGTG-3’ separated by five base pairs. The ChREBP-Mlx heterodimer is 
unable to bind the E-box motif located at –76/-81 in the APOA5 promoter whose the analysis 
shows the 5’-CACGTG5TACTCA-3’ sequence. Thus, this is not a correct ChoRE for ChREBP 
and this reinforces the specific implication of USF as transcription factor in the APOA5 gene 
regulation by glucose. 
In conclusion, we show here that D-glucose, through a metabolite generated at the beginning of 
glycolysis, activates the PP1/PP2A signalling pathway and increases the regulation of APOA5 
gene in cells. This activation of phosphatases mediates the dephosphorylation of USF1/2 
transcription factors, and thus, their specific binding to the E-box element in the APOA5 
promoter, driving to the APOA5 transactivation. These important new data strengthen the 
relation between APOA5 and alteration in glucose homeostasis, metabolic disorder and 
modulation in triglyceride levels observed in the physiopathology of diabetes. 
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MATERIALS AND METHODS 
 
Cell Culture and Transfection Assays. 
Hepatoma HepG2 and HuH7 cells were grown in Dulbecco’s modified Eagles’s medium 
supplemented with 10% foetal calf serum, streptomycin/penicillin, sodium pyruvate, glutamine 
and nonessential amino acids (Invitrogene) at 37°C in a humidified 5% CO2 atmosphere. The 
medium was changed every 48h. Primary rat hepatocytes were isolated and cultured as 
described 18. Before treatment cells were deprived for D-glucose during 18h. Human APOA5 
promoter fragments (residues -304/+63, -146/+63 and -61/+63) or L-PK glucose-responsive 
promoter were cloned in the pGL3 luciferase vector. Site-directed mutagenesis (Stratagene) for 
the E-box 5’-CACGTG- 3’ located in the –146/+63 promoter fragment was done to obtained 
the mutated E-box 5’-CCCGCG-3’ (mutated bases are indicated in bold). Transient 
transfection assays were performed using jetPEI cationic polymer transfection reagent (Q-
biogene) and luciferase activity was measured by using the Mithras LB 940 plate reader 
(Berthold Technologies). Transfection efficiency was monitored by co-transfecting 300 ng of 
cytomegalovirus –driven β–galactosidase expression plasmid. For Okadaic acid treatment, 
inhibitor was added to culture media 1h prior to D-glucose to abolish the protein phosphatases 
PP1 and PP2A signalling pathway. The same volume (less than 0.1% of the total volume of the 
culture media) of DMSO was used as control. To determine the metabolic pathway involved in 
the D-glucose regulation, cells were treated in the same conditions with glucose analogs and 
metabolites as indicated in Figure 2. Independent experiments were done at least three times in 
triplicate. The data were expressed as mean ± SD. Statistic significance were assessed with the 
Student’s t test. 
 
RNA Extraction and Quantification. 
Total RNA was isolated from cells using NucleoSpin RNA II kit (Macherey-Nagel). 
Quantification analysis was performed after a reverse transcription by using random hexamere 
primers with the Omniscript Reverse transcriptase kit (Qiagen) followed by a real-time PCR 
using the MX 4000 apparatus (Stratagene). APOA5 mRNA was quantified and normalized with 
the 36B4 gene, which codes for the human acidic ribosomal phosphoprotein. Specific primers 
used for the amplifications are as follow: human APOA5 forward: 5’-ACG CAC GCA TCC 
AGC AGA AC-3’; human APOA5 reverse: 5’-TCG GAG AGC ATC TGG GGG TC-3’; rat 
apoa5 forward: 5’-GCC TGG GAA GGA GCC TCC TCG GC-3’; rat apoa5 reverse: 5’-GCT 
CCA TCA GCT CGA CCG TGT AGG G-3’; 36B4 forward: 5’-CAT GCT CAA CAT CTC 
CCC CTT CTC C-3’; and 36B4 reverse: 5’-GGG AAG GTG TAA TCC GTC TCC ACA G-3’. 
The PCR amplifications were performed with the Brilliant Quantitative PCR Core Reagent kit 
as recommended by the manufacturer (Stratagene). Independent experiments were done at least 
three times in triplicate. Quantification of mRNA levels was expressed relative to control as 
means ± standard deviation (SD). After siRNA experiments, quantification of mRNA levels 
was done for each gene by real-time PCR with the specific oligonucleotides, and normalized 
with the 36B4 gene. 
 
Electrophoretic Mobility Shift Assay (EMSA), Oligonucleotide Precipitation Assay, 
Chromatin Immunoprecipitation (ChIP) Assay and Western Blot Analysis. 
To detect the association of nuclear proteins with human APOA5 promoter in vitro and in vivo, 
EMSA, biotinylated oligonucleotide precipitation and ChIP assays were conducted as 
previously described 18. Each binding experiment was done at least three times using 
independent nuclear extracts. Three samples per condition were pooled to amplify the signal 
for precipitation assays. 
Small Interfering RNAs (SiRNAs). 
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Pre-designed small interfering RNA targeting USF1, USF2, PP1, and PP2A mRNA were 
provided by Ambion. Cells were plated at a density of 250 000 cells/well into 6-well plates and 
were transfected with 20 nM of siRNA for 8h using the siPORT Amine transfection agent as 
recommended by the manufacturer (Ambion). After 48h treatment with 5 mM or 25 mM D-
glucose, mRNA extraction and analysis were performed as described under “RNA extraction 
and Quantification”. 
 
Statistical Analysis. 
Statistical significance was analysed by using the Student t test. All values are reported as mean 
±SD. Values with asterisks were considered significant.  
(*:0.01<p<0.05, **:0.0001<p<0.01, and ***:p<0.0001). 
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Figure 1. D-glucose increases APOA5 gene expression in a time- and dose-dependent 
manner in human hepatoma cells and in primary rat hepatocytes. 
HepG2 and HuH7 were cultured A) for different times with D-glucose 25mM, and B) for 48h 
with different concentrations of D-glucose. Results are expressed in fold induction of APOA5 
gene expression relative to control obtained with cells treatment with D-glucose 5mM. C) 
Primary rat hepatocytes were cultured for 24h and 48h with D-glucose 25mM. Fold induction 
of apoa5 gene expression after D-glucose treatment is shown (black bars) versus control (white 
bars). For each experiment, results are representative of three independent treatments (means ± 
SD, n=3) (*:0.01<p<0.05, **:0.0001<p<0.01, and ***:p<0.0001). 
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Figure 2. Effect of D-glucose analogs and metabolites on APOA5 gene expression. 
APOA5 mRNA levels were measured in HuH7 cells cultured for 48 h in medium containing 
different chemicals as indicated. Fold induction of APOA5 gene expression after treatment is 
shown (black bars) versus control (white bars). Data are expressed as means ± SD, n=3. 
(***:p<0.0001). 
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Figure 3. D-glucose regulates the APOA5 gene expression at the transcriptional level 
through an E-box element in the promoter. 
A) HepG2 cells were transient transfected with luciferase reporter plasmid containing the  
–304/+63 human APOA5 promoter fragment or the L-PK glucose responsive promoter 
promoter (full bars) or the control vector pGL3 (stripped bars). Cells were treated with 
different concentrations of D-glucose for 48 h and luciferase activity was measured. B) HepG2 
cells were transfected with luciferase reporter constructs containing a series of 5’-deletions of 
the APOA5 promoter, with or without the wild-type E-box 5’-CACGTG-3’ (black element) or 
the mutated E-box 5’-CCCGCG-3’ (hatched element). Luciferase activity was measured and 
normalized according to β-galactosidase activity as described under “Experimental 
procedures”. Results are expressed as mean ± SD, n=3. Independent assays were repeated at 
least three times and the representative result is shown (**:0.0001<p<0.01, and ***:p<0.0001).  
0 1 2 3
Fold 
-61 
- E-
- E-
* 
*
* 
- E-
B
+6
+6
+6
+6
5mM D-
25mM D-
Figure 3 
A
0
5
10
15
20
25
L
u
ci
fe
ra
s
e 
a
ct
iv
pGL LPAPOA
* * 
* * 
 13
 
 
Figure 4. USF1 and USF2 specifically bind in vitro and in vivo the E-box element in the 
APOA5 promoter. 
A) EMSA were performed at least three times using independent nuclear extracts (NE) from 
HepG2 cells treated during 48h with 5mM D-glucose or 25mM D-glucose and with in vitro 
transcribed-translated (TNT) human USF1 protein or unprogrammed reticulocyte lysate. Three 
probes were used for experiments: an USF consensus E-box as the control (con) probe, a wild 
type (WT) APOA5 E-box containing probe, and a mutated (mut) APOA5 E-box containing 
probe. Antibodies (Ab) against USF1, USF2 or SREBP-1c were added to check the specificity 
of the nucleoproteins. B) Immunoblot of the transcribed-translated human USF1 protein and 
APOA5 bound-USF1 from nuclear extracts. Quantification of the USF1/promoter association 
after three independent biotinylated oligoprecipitation assays (**:0.0001<p<0.01). C) 
Formaldehyde-cross-linked chromatin isolated from cells was immunoprecipitated with USF1 
antibody. In vivo USF1/promoter association was evaluated by PCR. Negative (PCR-) and 
positive controls were obtained after PCR amplification with no sample and plasmid containing 
the –304/+63 APOA5 promoter fragment respectively. ChIP assays were repeated 
independently three times and multiple samples were pooled in each experiment 
(**:0.0001<p<0.01). 
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Figure 5. Effect of D-glucose on USF1 and USF2 mRNA and protein levels. 
A) USF1 and USF2 mRNA levels were quantified by RT-PCR and normalized with the 36B4 
gene after HuH7 treatment with 5mM or 25mM D-glucose for 48h. B) Western blot analyses of 
USF1 and USF2 protein levels using nuclear extracts from cells treated with 5mM or 25mM D-
glucose for 48h. In both immunoblots, in vitro transcribed-translated human USF1 protein or 
unprogrammed reticulocyte lysate were used as controls to verify the specificity of antibodies. 
C) Quantification of USF1 or USF2 expressed as the USF1 or USF2 to β-actin protein ratio. 
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Figure 6. D-glucose activates the PP1/PP2A protein phosphatases signalling pathway. 
The phosphatases inhibitor okadaic acid was added to HuH7 cells for 1h before D-glucose 
treatment. The same volume of vehicle (DMSO) was used as the negative control. Fold 
induction of APOA5 gene expression are shown (means ± SD, n=3). Experiments were 
repeated at least three times and the representative result is shown (**:0.0001<p<0.01, and 
***:p<0.0001). 
 
Figure 
7. Effect of USF1, USF2, PP1 and PP2A siRNA on APOA5 gene expression. 
A) Expression of target genes after siRNA transfections was evaluated by quantification of 
mRNA levels with RT-PCR. B) HuH7 cells were transfected for 8h with specific siRNAs or 
nonspecific control siRNA (con) and subsequently treated with 5mM D-glucose or 25mM D-
glucose for further 48h. Experiments were repeated at least three times and APOA5 mRNA 
levels were analysed by quantitative RT-PCR. Values are expressed as mean ± SD. Results are 
representative of three independent assays. (**:0.0001<p<0.01, and ***:p<0.0001). 
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